Role of interferon for the treatment of myeloma

Shuhei Tomita, Shinichiro Okamoto

研究成果: Review article査読

抄録

Interferon (IFN)-alpha inhibits the growth of myeloma cell lines by inducing apoptosis. Based upon this finding, IFN has been evaluated in clinical trials as single-agent induction therapy, induction in combination with chemotherapy, and as maintenance therapy in plateau phase. Available data suggest that progression-free survival is improved with IFN, but the survival benefit is small. IFN has also been evaluated as maintenance after high-dose chemotherapy; however, the true benefit of IFN maintenance remains to be elucidated in view of conflicting data. In an area of rapidly increasing treatment options, novel agents, which have less toxicity and more biologic rationale, outweigh the limited benefits for IFN.

本文言語English
ページ(範囲)2285-2290
ページ数6
ジャーナルNippon rinsho. Japanese journal of clinical medicine
65
12
出版ステータスPublished - 2007 12月

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「Role of interferon for the treatment of myeloma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル